Royalty Pharma
RPRX
RPRX
442 hedge funds and large institutions have $9.86B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 85 funds opening new positions, 156 increasing their positions, 146 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 146
0.92% more ownership
Funds ownership: 72.15% → 73.08% (+0.92%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Holders
442
Holding in Top 10
7
Calls
$89M
Puts
$34.2M
Top Buyers
| 1 | +$405M | |
| 2 | +$159M | |
| 3 | +$82.3M | |
| 4 |
Morgan Stanley
New York
|
+$46.6M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$32.4M |
Top Sellers
| 1 | -$334M | |
| 2 | -$65.6M | |
| 3 | -$60.4M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$55.3M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$51.2M |
